Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BP1001 with Venetoclax and Decitabine in AML
NCT02781883Phase 2Recruiting
- Sponsor
- Bio-Path Holdings, Inc.
- Start
- May 2016
- Primary completion
- Dec 2027
- Modality
- Nanoparticles, Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 2, open-label trial of prexigebersen in acute myeloid leukemia (AML) (3 arms), sponsored by Bio-Path Holdings, Inc. Primary endpoint: Complete Remission, Complete Remission with incomplete hematologic recovery, Complete Remission with partial hematologic recovery at 180 days. Started May 2016; status: recruiting.
02
Drugs
prexigebersen
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02781883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02781883.